↓ Skip to main content

Dove Medical Press

Article Metrics

Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran

Overview of attention for article published in Vascular Health and Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
62 Mendeley
Title
Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran
Published in
Vascular Health and Risk Management, January 2015
DOI 10.2147/vhrm.s62595
Pubmed ID
Authors

Christina Cove

Abstract

Venous thromboembolism (VTE) is a disease state that carries significant morbidity and mortality, and is a known cause of preventable death in hospitalized and orthopedic surgical patients. There are many identifiable risk factors for VTE, yet up to half of VTE incident cases have no identifiable risk factor and carry a high likelihood of recurrence, which may warrant extended therapy. For many years, parenteral unfractionated heparin, low-molecular weight heparin, fondaparinux, and oral vitamin K antagonists (VKAs) have been the standard of care in VTE management. However, limitations in current drug therapy options have led to suboptimal treatment, so there has been a need for rapid-onset, fixed-dosing novel oral anticoagulants in both VTE treatment and prophylaxis. Oral VKAs have historically been challenging to use in clinical practice, with their narrow therapeutic range, unpredictable dose responsiveness, and many drug-drug and drug-food interactions. As such, there has also been a need for novel anticoagulant therapies with fewer limitations, which has recently been met. Dabigatran etexilate is a fixed-dose oral direct thrombin inhibitor available for use in acute and extended treatment of VTE, as well as prophylaxis in high-risk orthopedic surgical patients. In this review, the risks and overall benefits of dabigatran in VTE management are addressed, with special emphasis on clinical trial data and their application to general clinical practice and special patient populations. Current and emerging therapies in the management of VTE and monitoring of dabigatran anticoagulant-effect reversal are also discussed.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Slovenia 1 2%
Unknown 61 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 21%
Student > Master 8 13%
Researcher 7 11%
Other 6 10%
Student > Postgraduate 5 8%
Other 14 23%
Unknown 9 15%
Readers by discipline Count As %
Medicine and Dentistry 32 52%
Nursing and Health Professions 5 8%
Agricultural and Biological Sciences 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Psychology 1 2%
Other 6 10%
Unknown 13 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2015.
All research outputs
#2,585,530
of 5,218,786 outputs
Outputs from Vascular Health and Risk Management
#165
of 338 outputs
Outputs of similar age
#90,304
of 174,068 outputs
Outputs of similar age from Vascular Health and Risk Management
#5
of 14 outputs
Altmetric has tracked 5,218,786 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 338 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,068 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.